Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698776 · ClinicalTrials.gov registry record · Phase 1
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00698776 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT00698776, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single arm open label trial to test the tolerability of the combination of monocyte derived DCs loaded with KRN7000 (DC-KRN7000) and Lenalidomide (LEN) in patients with asymptomatic myeloma. Phase I component of the study will evaluate the optimal dose of LEN, with particular emphasis on safety. After an interim analysis of these data, a single dose level will be chosen for phase II component in additional patients.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Monocyte derived DCs loaded with KRN7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698776
The ClinicalTrials.gov registry entry for NCT00698776 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00698776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698776 about?
NCT00698776 is a clinical study titled "Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma". This is a single arm open label trial to test the tolerability of the combination of monocyte derived DCs loaded with KRN7000 (DC-KRN7000) and Lenalidomide (LEN) in patients with asymptomatic myeloma. Phase I component of the study will evaluate the optimal dose of LEN, with particular emphasis on s...
What is the current status of trial NCT00698776?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00698776?
The interventions under investigation include: Lenalidomide (DRUG), Monocyte derived DCs loaded with KRN7000 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00698776?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.